Top Biotech Companies in London (199)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Galleri and total revenue have risen consistently, with full-year 2025 up 17% and U.S. Galleri up 26%, followed by Q1–Q2 2026 total revenue gains of 28% and 26% alongside 50% and 35% volume growth. This cadence, including Q4 2025 Galleri revenue up 31%, indicates sustained commercial momentum after the June 2024 spin‑off.
Strategic Partnerships: Channel and platform integrations such as Epic EHR and Quest Diagnostics, plus collaborations like Samsung for Asian commercialization, are expanding access and streamlining ordering. Additional distribution wins (e.g., Priority Health employer plans and digital health channels) reinforce multi‑channel penetration for Galleri.
Investor Backing & Capital Strength: The company reports a substantial cash balance (~$861.6M as of Q2 2026) and closed a $110M equity financing with Samsung, bolstering financial flexibility. Public listing post‑spin‑off further enhances capital‑markets access to fund trials and commercialization.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Market Expansion: International partnerships across the UK, Germany, and Japan—culminating in a first Scottish agreement in 2026—are described as tripling the network in 2025 and adding nearly 70% ex‑U.S. growth in 2026. These moves indicate a materially broader geographic footprint for evidence generation.
Strategic Partnerships: Collaborations with organizations such as NHS Greater Glasgow and Clyde, Quest Diagnostics, Abbott, TailorMed, and Unicancer reflect deepening integration at the point of care and with research stakeholders. These relationships suggest expanding routes to market and data acquisition.
Product Line Growth: New offerings like Flatiron Telescope, AI‑powered oncology datasets, and an AI data‑quality/validation framework signal active investment in products and capabilities. Conference acceptances at ISPOR/ASCO/WCLC in 2026 further underscore ongoing commercialization and scientific engagement.
Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician...
At CN Innovations, we aim to create a better world through meaningful technological innovations. Our business revolves around incubating impactful advanced manufacturing technologies and providing world-class technological and supply chain solutions to our clients.
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace...
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our...
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Creating Possible drives everything we do. It’s evident in our...
Gilead Sciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader in HIV and maintains a top position in CAR‑T (Yescarta) while building a credible oncology footprint. Leadership is reinforced by durable HIV demand across treatment and prevention, with new lenacapavir offerings extending the franchise.
Resilient & Sustainable Growth: Recent results show modest headline growth with stronger momentum in the core base business and management guiding to continued base‑business expansion in 2026. COVID normalization and CAR‑T competition moderate the pace, but HIV and liver disease strength provide steady underpinning.
Future-Ready Strategy: The pipeline advances lenacapavir‑based regimens and multiple oncology programs, with near‑term launches and read‑throughs that can support growth beyond 2026. Prevention initiatives and oncology scaling are positioned as key execution pillars for medium‑term expansion.
Founded in 1997, Ergomed is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with...
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology,...
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using...
Sitero is a next-generation, site-focused clinical research organization (CRO) for life sciences and institutional research organizations that helps get treatments to market safer and faster through tech-forward services that streamline research. Accelerate your clinical trial, drive compliance and safety, and unlock innovation with access to powerful technology and world-class services. Sitero combines the expertise of a tenured team with a...
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
Princeton Biopartners is a best-in-class provider of integrated consulting solutions to the life sciences sector. Our mission is to improve the evidence base, accessibility, and impact of biomedical innovations through strategic advisory, software, and our venture fund. We pride ourselves on establishing long-term client relationships and are dedicated to addressing pain points via integrated and transformative projects. Setting new standards...
Planet Pharma was founded by a dedicated team of seasoned professionals with extensive experience supporting the pharmaceutical, biotechnology and device industries. Our goal was to create an organization that strengthens the employer-employee dynamic by connecting clients with talent — ultimately making staffing more personal and creating enduring, valuable relationships. We are able to achieve this by leveraging cutting-edge technology and flexible...
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products...
IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and...
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
GlamorousAI is bringing drugs to every target though its AI-first SaaS platform for drug discovery, RosalindAI. RosalindAI advancing AI to address small, noisy and sparse data challenges with a technology validated experimentally in the lab.
We are a global manufacturer of raw materials and a producer of energy used in everyday life. From medicines to mobile phones, agriculture to automotive, our products enhance standards of living for everyone around the world. We understand the challenge the world is facing, and we are working hard to help economies, businesses and individuals deliver a zero carbon emissions...
